Researchers make key discovery in fight against Alzheimer's disease

Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.

Jack Jhamandas, a researcher with the Faculty of Medicine & Dentistry at the U of A, is the principal investigator with the team whose research results were recently published in the peer-reviewed publication The Journal of Neuroscience. He works in the Division of Neurology.

The team took brain tissue from animal models with and tested the tissue in the lab, looking specifically at the cells' capacity. When brain cells are shocked by a barrage of electrical impulses, the cells "remember" the experience and this is a typical way to test or measure memory in the lab setting.

Amyloid protein, which is found in abnormally large amounts in the memory and cognition parts of the brains of Alzheimer's patients, diminishes memory. A sister protein, known as amylin, which comes from the pancreas of diabetic patients, has the same impact on memory cells.

Jhamandas and his team demonstrated last year that a drug that never made it to market, known as AC253, could block the toxic effects of amyloid protein that lead to brain cell death.

In the lab, Jhamandas and his teammates, which included Ryoichi Kimura, a visiting scientist from Japan, tested the memory of normal brain cells and those with Alzheimer's—both from animal models. When the drug AC253 was given to brain cells with Alzheimer's and the shock memory tests were redone, memory was restored to levels similar to those in normal cells.

"This is very important because it tells us that drugs like this might be able to restore memory, even after Alzheimer's disease may have set in," says Jhamandas.

His team is continuing their research in this area and wants to see if the drug, when given before symptoms appear, can "stop the impairment of behaviour and cognition altogether in animals destined to develop Alzheimer's," says Jhamandas. Their continued research tests will take a least a year to complete.

He noted it is difficult for AC253 to cross the brain barrier, so research teams in pharmaceutical companies would need to design a similar drug that is easier to penetrate . Jhamandas says if the tests are successful, he thinks clinical trials could start within about five years, but he stressed that further testing needs to be done before such trials can occur.

"I think what we discovered may be part of the solution, but I can't say it will be the solution. There is a long list of drugs and approaches that haven't panned out as expected in the fight against Alzheimer's. I don't think one drug or approach will solve Alzheimer's disease because it's a complicated disease, but I am cautiously optimistic about our discovery and its implications."

The Canadian Institutes of Health Research funded the work of Jhamandas and his team.

"An estimated 1,125,000 Canadians will be diagnosed with Alzheimer's over the coming 30 years," said Yves Joanette, Scientific Director of the CIHR Institute of Aging. "To respond to this growing health care challenge, CIHR developed the International Collaborative Research Strategy for Alzheimer's Disease. The strategy aims to give Canadians rapid access to the latest approaches to preventing, diagnosing and treating Alzheimer's Disease and related dementias. The findings by Dr. Jhamandas could eventually help reduce the personal, social and economic impacts for Alzheimer's Disease."

Related Stories

Scientists find new cause of Alzheimer's

Apr 19, 2006

Belgium researchers say they are the first to demonstrate the quantity of amyloid protein in brain cells is a major factor of Alzheimer's disease.

Road block as a new strategy for the treatment of Alzheimer's

Aug 22, 2011

Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Anti-inflammatory drug blocks brain plaques

Jun 24, 2008

Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells. Scientists had previously shown that ...

Recommended for you

The long reach of Alzheimer's disease

Apr 08, 2014

To address the burgeoning demands of Alzheimer's disease that will affect generations, new policies will have to be adopted to acknowledge the complex and unique needs of people with dementia.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Argiod
2 / 5 (2) Dec 12, 2012
If this works out, they will have two drugs that can wipe out memory, then restore the memory process to allow imprinting of new memories. I'll bet the CIA and other covert agencies will love this.